Comorbidities are coexisting diseases that are distinct from the primary illness for which a patient seeks health care services 1. Comorbidity may affect detection, prognosis, therapy, and outcome of the primary disease. We recently published a paper evaluating the role of comorbidities in the survival of patients with myelodysplastic syndromes, in which Charlson index was utilized as the measure of comorbidities 2.
Charlson et al. developed a weighted index measure of comorbidities based on medical records review and identified a total of 19 conditions that influence mortality 3. Both the number and the seriousness of comorbid conditions were taken into account. Each of the 19 conditions was assigned a weight (0 - 6) according to its potential for influencing mortality. A patient's comorbidity index would be the sum of all weighted comorbidities. A higher score on the Charlson index indicates a greater burden of comorbid conditions. Later, Deyo et al. adapted the Charlson index for use with the ICD-9-CM diagnostic and procedure codes available in administrative datasets 4. Researchers at the National Cancer Institute subsequently developed a SAS macro to calculate Charlson index for linked SEER*Medicare data (http://healthservices.cancer.gov/seermedicare/program/comorbidity.html). We adopted this method to calculate Charlson index for the more than 2,000 patients included in our study.
Acknowledgments
X. Ma was supported by a grant from the National Cancer Institute (K07 CA119108). None of the authors have potential conflict of interest or competing financial interests.
Footnotes
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
References
- 1.Finstein AR. The pre-therapeutic classification of co-morbidity in chornic disease. J Chron Dis. 1970;23:455–468. doi: 10.1016/0021-9681(70)90054-8. [DOI] [PubMed] [Google Scholar]
- 2.Wang R, Gross CP, Halene S, Ma X. Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leuk Res. 2009 doi: 10.1016/j.leukres.2009.02.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383. doi: 10.1016/0021-9681(87)90171-8. [DOI] [PubMed] [Google Scholar]
- 4.Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–619. doi: 10.1016/0895-4356(92)90133-8. [DOI] [PubMed] [Google Scholar]